Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Seagate Technology Holdings PLC (STX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Seagate Technology Holdings PLC — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.53 (market cap $5.07B), while Seagate Technology Holdings PLC trades at $880.45 (market cap $185.97B). The key difference: Seagate Technology Holdings PLC is far larger — about 36.7× ACADIA Pharmaceuticals Inc.'s market cap, and Seagate Technology Holdings PLC pays a 0.36% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | STX | |
|---|---|---|
Market Cap | $5.07B | $185.97B |
Sector | Health | Technology |
52-Week High | $29.41 | $1.09K |
52-Week Low | $20.06 | $154.43 |
Enterprise Value | $4.19B | $188.12B |
Dividend Yield | — | 0.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.
Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.
Seagate Technology (STX) trades at $800.74, down 1.48% today, with a bearish technical signal but strong recent earnings beats driven by AI storage demand. The company reported Q2 2026 EPS of $5.71, beating expectations of $5.10, with revenue growth and margin expansion supported by its HAMR technology and data center contracts. However, high valuation ratios (P/E 59.03, P/S 15.41) and negative shareholder equity pose fundamental concerns.
The outlook is mixed: AI-driven demand and analyst bullishness (54.91% buy ratings) support upside to the $1,130 consensus target, but elevated valuation, legal settlements, and competitive pressures in the storage market present significant risks. Cash flow volatility and debt levels require monitoring for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Seagate Technology Holdings PLC
Seagate is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital
Read more on STX →
